Literature DB >> 31746370

DNA methylation of GHSR, GNG4, HOXD9 and SALL3 is a common epigenetic alteration in thymic carcinoma.

Reina Kishibuchi1, Kazuya Kondo1, Shiho Soejima1, Mitsuhiro Tsuboi2, Koichiro Kajiura2, Yukikiyo Kawakami2, Naoya Kawakita2, Toru Sawada2, Hiroaki Toba2, Mitsuteru Yoshida2, Hiromitsu Takizawa2, Akira Tangoku2.   

Abstract

Thymic epithelial tumors comprise thymoma, thymic carcinoma and neuroendocrine tumors of the thymus. Recent studies have revealed that the incidence of somatic non‑synonymous mutations is significantly higher in thymic carcinoma than in thymoma. However, limited information is currently available on epigenetic alterations in these types of cancer. In this study, we thus performed genome‑wide screening of aberrantly methylated CpG islands in thymoma and thymic carcinoma using Illumina HumanMethylation450 K BeadChip. We identified 92 CpG islands significantly hypermethylated in thymic carcinoma in relation to thymoma and selected G protein subunit gamma 4 (GNG4), growth hormone secretagogue receptor (GHSR), homeobox D9 (HOXD9) and spalt like transcription factor 3 (SALL3), which are related to cancer. We examined the promoter methylation of 4 genes in 46 thymic epithelial tumors and 20 paired thymus tissues using bisulfite pyrosequencing. Promoter methylation was significantly higher in thymic carcinoma than in thymoma and revealed a high discrimination between thymic carcinoma and thymoma in all 4 genes. Promoter methylation was higher in thymic carcinoma than in the thymus. No significant differences were observed in the promoter methylation of GNG4, HOXD9, or SALL3 between thymoma and the thymus. The promoter methylation of the 4 genes was not significantly higher in advanced‑stage tumors than in early‑stage tumors in all thymic epithelial tumors. Among the 4 genes, relapse‑free survival was significantly worse in tumors with a higher DNA methylation than in those with a lower DNA methylation in all thymic epithelial tumors. Moreover, relapse‑free survival was significantly worse in thymomas with a higher DNA methylation of HOXD9 and SALL3 than in those with a lower DNA methylation. On the whole, the findings of this study indicated that the promoter methylation of cancer‑related genes was significantly higher in thymic carcinoma than in thymoma and the thymus. This is a common epigenetic alteration of high diagnostic value in thymic carcinoma and may be involved in the carcinogenesis of thymic carcinoma. However, epigenetic alterations in the 3 genes, apart from GHSR, are not involved in the tumorigenesis of thymoma.

Entities:  

Year:  2019        PMID: 31746370     DOI: 10.3892/ijo.2019.4915

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  14 in total

1.  Promotor methylation status of MAPK4 is a novel epigenetic biomarker for prognosis of recurrence in patients with thymic epithelial tumors.

Authors:  Wei Guan; Songlin Li; Zhimin Zhang; He Xiao; Juan He; Jian Li; Xuan He; Jia Luo; Yun Liu; Lin Lei; Jungang Ma; Lizhao Chen; Chuan Chen
Journal:  Thorac Cancer       Date:  2022-09-08       Impact factor: 3.223

2.  GAD1 expression and its methylation as indicators of malignant behavior in thymic epithelial tumors.

Authors:  Shiho Soejima; Kazuya Kondo; Mitsuhiro Tsuboi; Kyoka Muguruma; Bilguun Tegshee; Yukikiyo Kawakami; Koichiro Kajiura; Naoya Kawakita; Hiroaki Toba; Mitsuteru Yoshida; Hiromitsu Takizawa; Akira Tangoku
Journal:  Oncol Lett       Date:  2021-04-21       Impact factor: 2.967

3.  Identification of methylation-driven genes related to the prognosis of papillary renal cell carcinoma: a study based on The Cancer Genome Atlas.

Authors:  Zeyu Liu; Yuxiang Wan; Ming Yang; Xuewei Qi; Zhenzhen Dong; Jinchang Huang; Jingnan Xu
Journal:  Cancer Cell Int       Date:  2020-06-12       Impact factor: 5.722

4.  Investigation of MLH1, MGMT, CDKN2A, and RASSF1A Gene Methylation in Thymomas From Patients With Myasthenia Gravis.

Authors:  Fabio Coppedè; Roberta Ricciardi; Angela Lopomo; Andrea Stoccoro; Anna De Rosa; Melania Guida; Loredana Petrucci; Michelangelo Maestri; Marco Lucchi; Lucia Migliore
Journal:  Front Mol Neurosci       Date:  2020-10-23       Impact factor: 5.639

5.  Molecular heterogeneity of guanine nucleotide binding-protein γ subunit 4 in left- and right-sided colon cancer.

Authors:  Jintian Song; Jianwei Yang; Rongbo Lin; Xiongchao Cai; Liang Zheng; Yigui Chen
Journal:  Oncol Lett       Date:  2020-10-07       Impact factor: 2.967

6.  Correlation among VEGFR3 gene promoter methylation, protein overexpression, and clinical pathology in early gastric cancer.

Authors:  Xiu-Feng Li; Ting-Guo Zhang; Yun-Xiang Zhang
Journal:  Transl Cancer Res       Date:  2020-05       Impact factor: 1.241

7.  Novel diagnostic and prognostic biomarkers of colorectal cancer: Capable to overcome the heterogeneity-specific barrier and valid for global applications.

Authors:  Yasir Hameed; Muhammad Usman; Shufang Liang; Samina Ejaz
Journal:  PLoS One       Date:  2021-09-02       Impact factor: 3.240

8.  HOX cluster and their cofactors showed an altered expression pattern in eutopic and ectopic endometriosis tissues.

Authors:  Fereshteh Esfandiari; Fereshteh Chitsazian; Masoumeh Golestan Jahromi; Raha Favaedi; Masood Bazrgar; Reza Aflatoonian; Parvaneh Afsharian; Abbas Aflatoonian; Maryam Shahhoseini
Journal:  Reprod Biol Endocrinol       Date:  2021-09-01       Impact factor: 5.211

Review 9.  SALL Proteins; Common and Antagonistic Roles in Cancer.

Authors:  Claudia Álvarez; Aracelly Quiroz; Diego Benítez-Riquelme; Elizabeth Riffo; Ariel F Castro; Roxana Pincheira
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

10.  High GNG4 expression is associated with poor prognosis in patients with lung adenocarcinoma.

Authors:  Bodong Zhou; Wenbo Zhu; Shuai Yuan; Yifei Wang; Qing Zhang; Hong Zheng; Lei Zhu; Jie Xu
Journal:  Thorac Cancer       Date:  2021-12-23       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.